Literature DB >> 7496439

Effect of vasoactive intestinal peptide and acetylcholine on penile erection in the rat in vivo.

J K Suh1, K H Mun, C K Cho, H C Shin, Y S Kim, T C Park.   

Abstract

We investigated the effect of vasoactive intestinal peptide (VIP) and its combination with acetylcholine (ACh) on the erectile response in 52 adults rats. Intracavernous injection of VIP (10(-8) to 10(-5)M, ACh (10(-9) to 10(-5), or a combination of VIP (10(-7) to 10(-5) with ACh (10(-6 M) additively enhanced that erection but did not lead to a full erection. VIP-antagonist (10(-9) to 10(-5 M), as well as atropine alone (10 (-7) to 10(-5 M), partially suppressed full erection induced by cavernous nerve stimulation (1 Hz, 3-6 V) in a dose-dependent manner, and the combination of VIP-antagonist (10(-9) to 10(-5 M) with atropine (10(-6 M) showed an additive effect. The results indicate that although VIP as well as ACh in involved in penile erection, they are not likely to be principal neurotransmitters. Their clinical application in the treatment of impotence may be confined to use in conjunction with another vasoactive agent.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7496439

Source DB:  PubMed          Journal:  Int J Impot Res        ISSN: 0955-9930            Impact factor:   2.896


  3 in total

1.  Loss of nitrergic neurotransmission to mouse corpus cavernosum in the absence of neurturin is accompanied by increased response to acetylcholine.

Authors:  Matthew R Nangle; Janet R Keast
Journal:  Br J Pharmacol       Date:  2006-05-08       Impact factor: 8.739

2.  Analysis of erectile responses to BAY 41-8543 and muscarinic receptor stimulation in the rat.

Authors:  George F Lasker; Edward A Pankey; Alexander V Allain; Jasdeep S Dhaliwal; Johannes-Peter Stasch; Subramanyam N Murthy; Philip J Kadowitz
Journal:  J Sex Med       Date:  2012-09-18       Impact factor: 3.802

Review 3.  Vasoconstriction and vasodilation in erectile physiology.

Authors:  Thomas M Mills
Journal:  Curr Urol Rep       Date:  2002-12       Impact factor: 2.862

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.